Proteomic Pattern in Female Stress Urinary Incontinence: a Pilot Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

40 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-11-30

Study Completion Date

2015-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Objective: The primary objective of the study is the comparison of protein concentrations between patients with stress urinary incontinence (SUI) and healthy controls.

Aim: This pilot study aims to determine a possible altered protein profile in women suffering from SUI, compared to healthy women and therefore to discriminate a potential protein biomarker for SUI.

Main outcome measure: mass spectrometric measuring of urinary proteomic secretome in diseased and healthy subjects (sequence coverage and number of identified proteins)

Trial design: Prospective case- control study

Setting: Department of Gynecology and Obstetrics of the Medical University of Vienna in co- operation with the Core Facilities Proteomics of the Medical University of Vienna

Population: Twenty female patients with SUI and twenty healthy patients who attend the outpatient clinic of the Department of Obstetrics and Gynaecology, Medical University of Vienna (sample size calculation FDR 0.05, power of 80%, assumed proportion of true H0 0.95, assumed standardized effect size of 1)

Methods: Examinations to be carried out: patient history, provocative stress test, ICIQ short form questionnaire, residual urine volume (ultrasound) and urine analysis (dipstick testing). A urine sample is obtained from the patient after spontaneous micturition, to which protease inhibitor will be added immediately. Two serum blood vials (each 9ml) are taken from a peripheral vein of the patient for routine laboratory and further research.

Proteomics analysis will be performed using chromatographic separation (LC) with mass spectrometric detection (MS).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Age-stratified Outcome of Pelvic Floor Muscle Exercise for Urinary Incontinence

NCT01445834

Stress Urinary Incontinence Urge Urinary Incontinence

COMPLETED

Pelvic Floor Contraction in Different Positions Among Women With and Without Stress Urinary Incontinence

NCT04288648

Urinary Stress Incontinence

COMPLETED

Pelvic Floor Displacement in Women With SUI and Healthy Women: An Ultrasound Study (Stress Urinary Incontinence)

NCT02930720

Healthy Stress Urinary Incontinence

UNKNOWN

Pelvic Floor Muscle Evaluation in Women With Stress Urinary and Urgency Urinary Incontinence

NCT01391780

Urinary Incontinence, Stress Urge Incontinence

COMPLETED

PFU vs. UDS in SUI

NCT06886997

Stress Urinary Incontinence (SUI)

NOT_YET_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Methods:

Sample preparation and analysis will include:

1. Sample collection and immediate addition of protease inhibitor cocktail (Roche, Complete Protease Inhibitor Cocktail).
2. Urine centrifugation and filtration for removal of cell debris.
3. Protein precipitation by applying methanol/chloroform separation for removal of all possible non-proteinic substances.
4. Protein digestion applying in-solution trypsin, pepsin, and Glu-C.
5. Peptide separation using nano HPLC and different chromatographic approaches.

1. Reversed phase (RP) separation of peptides and MS detection
2. Separation of peptides using HILIC (hydrophilic Interaction Liquid Chromatography) for discrimination of polar peptides.
3. In addition to RP and HILIC directly coupled to MS, digested peptides will be separated using multidimensional approaches. Weak anion exchange columns operated under HILIC conditions will be used to separate peptides carrying posttranslational modifications such as phosphorylation or acetylation, thus, increasing the dynamic range of detection. During this separation, fractions will be collected and re-injected onto the RP and HILIC with MS detection.
4. All nano HPLC separations will be performed using biocompatible separation system.

Mass spectrometric analysis of digested peptides will be performed using two different detection methods: ion-trap and the time-of-flight (qToF) MS. qToF mass spectrometric detection and analysis will also be used for the label-free quantitation of peptides and proteins detected in samples. All measurements will be performed in triplicate to provide corrections for technical variability of separation and ionization.

General database search will be performed using the Human SwissProt Database in its actual version at the time of analysis. Data search will be performed using Mascot (http://www.matrixscience.com/) and X!Tandem (http://www.thegpm.org/tandem/) search machines, and the final data allocation and filtering by using Scaffold (www.proteomsoftware.com).

Statistical analysis:

Data analysis will be conducted with the bioconductor package limma. Before data analysis, data will be filtered by excluding proteins with measurements with a low interquartile range. Groups will be compared by moderated paired t-statistics adjusting for age. Adjustment for multiple testing will be done by Benjamini-Hochberg correction controlling the FDR at 0.05.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Female Stress Urinary Incontinence

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

stress urinary incontinence

Patients presenting with stress urinary incontinence according to the inclusion and exclusion criteria

collection of urine and blood sample

Intervention Type OTHER

healthy controls

healthy women with the same inclusion and exclusion criteria as the case group, except for stress urinary incontinence

collection of urine and blood sample

Intervention Type OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

collection of urine and blood sample

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients with stress urinary incontinence: a history of symptoms of stress urinary incontinence for at least 3 months (including anamnestic complaints of involuntary leakage on effort or exertion or on sneezing or coughing) and a positive provocative stress test (defined as an observed transurethral loss of urine that was simultaneous with a cough or Valsalva maneuver at a bladder volume of 300ml or less)
* patients capable of independent toiling
* patients who are able to fully understand all study procedures and to provide written informed consent to study participation
* age ≥ 18
* patients after vaginal delivery

Exclusion Criteria

* patients who have previously been treated for SUI (both surgical or pharmacological treatment)
* patients who have a medical history of uncontrolled overactive bladder (OAB) or urinary incontinence other than SUI (including anamnestic complaints on involuntary urine leakage accompanied by or immediately preceded by urgency, not stress induced)
* patients with well established neurological disorder (e.g. Multiple Sclerosis, Parkinson's disease, Alzheimer's disease)
* patients with pelvic organ prolapse stage ≥ II (ICS classification)
* patients with a clinically significant bladder outlet obstruction and/or patients with a post void residual volume (PVR) \> 100ml
* patients with a history of acute urinary retention or history of repeated catheterizations due to acute urinary retention within the last 3 months prior to the day of informed consent
* patients with an indwelling catheter and patients practicing intermittent self- catheterization
* patients who have undergone a bladder biopsy or any other minor pelvic surgical intervention less than 30 days prior to the day of informed consent
* patients with a history of bladder cancer
* patients with acute or recurrent urinary tract infection and/or unexplained haematuria
* patients with stone(s) in the bladder or urethra and upper tract stone disease causing symptoms
* patients with evidence of renal insufficiency (creatinine \> 1.5x upper limit of normal)
* patients with evidence of hepatic disease (total bilirubin \>1.5x upper limit of normal, or AST or ALT or alkaline phosphatase \>2x upper limit of normal)
* patients with a history of alcohol and/or other drug abuse
* patients who are unable and/or unlikely to comprehend and follow the study procedures and instructions
* patients who are pregnant or lactating
* patients with serious medical conditions who, in the opinion of the investigators, should not participate in this study

Minimum Eligible Age

18 Years

Maximum Eligible Age

99 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes